Gilead inks $805M in-licensing deal with Jounce for preclinical immuno-oncology drug
The drug, JTX-1811, is designed to work by depleting certain T cells that suppress the immune system's response to tumors. A regulatory filing to begin clinical trials is expected in the first half of next year.